Launch of the European network of medical isotopes: Regulation & Safety


September 29, 2021

The PRISMAP network was recently launched and will see more than 20 European academic institutions and research centers pooling their knowledge, expertise and infrastructure to accelerate the introduction of new medical radioisotopes. The network aims to provide a sustainable source of new high purity radionuclides for medical research.

“One of the main limitations to the development of new radio-medicinal products is access to radionuclides during the developmental and early biomedical research phases,” said PRISMAP. “Within PRISMAP … we aim to enable this phase of development by providing access to new high purity radioisotopes for medical research.”

PRISMAP brings together a European consortium of the main sources of intense neutrons, mass isotope separation facilities and high power accelerators and cyclotrons, with leading biomedical and health research institutes in the active translation of emerging radionuclides in diagnostics and medical treatment. PRISMAP said it creates a single entry point for a “fragmented user community” spread across universities, research centers, industry, and hospitals, much like the National Isotope Development Center, supported by the US Department of Energy, provided sources of radionuclides. for users in the United States.

The PRISMAP consortium includes 23 partners including nine major European, national or regional infrastructures and four emerging “infrastructures”, as well as high-level research centers, hospitals, the Joint European Research Center and an SME. PRISMAP partners come from 13 different countries: Austria, Belgium, Denmark, France, Germany, Italy, Latvia, Norway, Poland, Portugal, Sweden, Switzerland and United Kingdom, under the coordination of CERN, the European Nuclear Research Laboratory.

A map showing the members of the consortium (Image: PRISMAP)

“The PRISMAP consortium brings together a set of key European, national and regional large production infrastructures, chosen specifically for their expertise in the production and shipment of unconventional radionuclides,” said PRISMAP. “PRISMAP’s research centers and hospitals all demonstrate key competencies in translational research and are essential to foster a new era of research based on emerging medical radionuclides. It is important to note that the PRISMAP community grows and strengthens over the years. research centers as well as emerging production facilities once operational. “

Through the PRISMAP consortium, the development towards increasing the production of new radioisotopes will be investigated, in the form of new production technology, new purification methods and proof of concept investigations showing the development of new treatments from the test bed to patient care. .

Access to radioisotopes and associated facilities will be granted on a “basis of selection of excellence”, requesting access to radioisotopes and, where applicable, additional biomedical facilities, via an access platform in line. A selection jury made up of experts in the fields of radioisotope production, molecular imaging and radionuclide therapy will select the best projects from the applicants. The first call for proposals will be launched before the end of this year for applications in the first quarter of 2022.

PRISMAP noted: “New facilities are on the horizon, such as the Jules Horowitz reactor at CEA Cadarache (France), the ISOL @ MYRRHA mass separation facility at SCK-CEN (Belgium), the new complex of SPES accelerators in the national laboratories of Legnaro of INFN (Italy), the European source of spallation in Lund (Sweden), and finally both the new SPIRAL2 installation at GANIL (France) which recently accelerated its first beams and the FAIR installation at GSI (Germany), construction of which is progressing. will directly benefit from the results of PRISMAP to increase production capacity across Europe. “

He said new data will be generated and compiled for the immediate and smooth adoption of the new radioisotopes in medical environments through collaboration between research hospitals and metrology institutes (such as the National Physical Laboratory from the United Kingdom). All new findings will be used to create new educational materials for professionals in the different fields of this multidisciplinary field, as well as to train the next generation of professionals and advise the European Commission on these emerging radioisotopes.

This PRISMAP project – which started on May 1 and will run until April 30, 2025 – has received funding of nearly 5.0 million euros (US $ 5.8 million) from the research program and Horizon 2020 innovation of the European Union.

Research and writing by World Nuclear News


About Author

Leave A Reply